Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

NAActive, not recruitingINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

August 17, 2016

Primary Completion Date

May 16, 2022

Study Completion Date

January 31, 2028

Conditions
Recurrent, Refractory, or High Risk LeukemiasMatched Targeted Therapy
Interventions
GENETIC

Leukemia Profiling

Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.

Trial Locations (15)

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10467

The Children's Hospital at Montefiore, The Bronx

14263

Roswell Park Comprehensive Cancer Center, Buffalo

19404

Children's Hospital of Philadelphia, Philadelphia

21287

Johns Hopkins Hospital, Baltimore

30322

Children's Healthcare of Atlanta, Atlanta

53226

Children's Hospital of Wisconsin, Milwaukee

55404

Children's Hospital's and Clinics of Minnesota, Minneapolis

60637

The University of Chicago, Chicago

63110

Washington University at St. Louis School of Medicine, St Louis

80045

Children's Hospital Colorado, Aurora

94158

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

98105

Seattle Children's Hospital, Seattle

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT02670525 - Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter